These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31415934)

  • 1. Immune Effects of M51R Vesicular Stomatitis Virus Treatment of Carcinomatosis From Colon Cancer.
    Day GL; Bryan ML; Northrup SA; Lyles DS; Westcott MM; Stewart JH
    J Surg Res; 2020 Jan; 245():127-135. PubMed ID: 31415934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus.
    Blackham AU; Northrup SA; Willingham M; D'Agostino RB; Lyles DS; Stewart JH
    Surgery; 2013 Mar; 153(3):333-43. PubMed ID: 23102637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma.
    Blackham AU; Northrup SA; Willingham M; Sirintrapun J; Russell GB; Lyles DS; Stewart JH
    J Surg Res; 2014 Apr; 187(2):412-26. PubMed ID: 24252853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
    Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo.
    Cary ZD; Willingham MC; Lyles DS
    J Virol; 2011 Jun; 85(12):5708-17. PubMed ID: 21450822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic vesicular stomatitis virus as a treatment for neuroendocrine tumors.
    Randle RW; Northrup SA; Sirintrapun SJ; Lyles DS; Stewart JH
    Surgery; 2013 Dec; 154(6):1323-29; discussion 1329-30. PubMed ID: 23973113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. M51R and Delta-M51 matrix protein of the vesicular stomatitis virus induce apoptosis in colorectal cancer cells.
    Gray Z; Tabarraei A; Moradi A; Kalani MR
    Mol Biol Rep; 2019 Jun; 46(3):3371-3379. PubMed ID: 31006094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vesicular Stomatitis Virus (VSV) G Glycoprotein Can Be Modified to Create a Her2/Neu-Targeted VSV That Eliminates Large Implanted Mammary Tumors.
    Gao Y; Bergman I
    J Virol; 2023 Jun; 97(6):e0037223. PubMed ID: 37199666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fusogenic vesicular stomatitis virus combined with natural killer T cell immunotherapy controls metastatic breast cancer.
    Nelson A; McMullen N; Gebremeskel S; De Antueno R; Mackenzie D; Duncan R; Johnston B
    Breast Cancer Res; 2024 May; 26(1):78. PubMed ID: 38750591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia.
    Betancourt D; Ramos JC; Barber GN
    J Virol; 2015 Dec; 89(23):11786-800. PubMed ID: 26378177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor control.
    Janelle V; Langlois MP; Lapierre P; Charpentier T; Poliquin L; Lamarre A
    Mol Ther; 2014 Jun; 22(6):1198-1210. PubMed ID: 24590047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential of recombinant vesicular stomatitis virus-mediated virotherapy against metastatic colon cancer.
    Yamaki M; Shinozaki K; Sakaguchi T; Meseck M; Ebert O; Ohdan H; Woo SL
    Int J Mol Med; 2013 Feb; 31(2):299-306. PubMed ID: 23232984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
    Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
    Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice.
    Ebert O; Harbaran S; Shinozaki K; Woo SL
    Cancer Gene Ther; 2005 Apr; 12(4):350-8. PubMed ID: 15565179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.
    Rommelfanger DM; Compte M; Grau MC; Diaz RM; Ilett E; Alvarez-Vallina L; Thompson JM; Kottke TJ; Melcher A; Vile RG
    Mol Ther; 2013 Feb; 21(2):348-57. PubMed ID: 23011032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent.
    Heiber JF; Barber GN
    J Virol; 2011 Oct; 85(20):10440-50. PubMed ID: 21813611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Creation of matrix protein gene variants of two serotypes of vesicular stomatitis virus as prime-boost vaccine vectors.
    Kim GN; Wu K; Hong JP; Awamleh Z; Kang CY
    J Virol; 2015 Jun; 89(12):6338-51. PubMed ID: 25855732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vesicular stomatitis virus is a potent agent for the treatment of malignant ascites.
    Zhou Y; Wen F; Zhang P; Tang R; Li Q
    Oncol Rep; 2016 Mar; 35(3):1573-81. PubMed ID: 26707610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer.
    Hastie E; Grdzelishvili VZ
    J Gen Virol; 2012 Dec; 93(Pt 12):2529-2545. PubMed ID: 23052398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RIG-I-mediated innate immune signaling in tumors reduces the therapeutic effect of oncolytic vesicular stomatitis virus.
    Zhang P; Han X; Tan W; Chen D; Sun Q
    Thorac Cancer; 2023 Jan; 14(3):246-253. PubMed ID: 36447430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.